Cingulate to Present at LD Micro Investor Conference

2022-10-20

KANSAS CITY, Kan., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Cingulate Therapeutics Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Cingulate Chairman & CEO Shane J. Schaffer will present at the LD Micro Main Event XV investor conference on October 26, 2022. Conference and presentation details are as follows: Event: LD Micro Main Event XV Date: Wednesday, October 26, 2022 Presentation: 10:00 a.m. Pacific Time Live stream: Location: Luxe Sunset Boulevard Hotel, Los Angeles Management will host individual investor meetings. To arrange a meeting with Cingulate, please contact your conference representative. Investors may also contact Cingulate investor relations at mkreps@darrowir.com to arrange an in-person meeting. About Cingulate® Cingulate Inc. (NASDAQ: CING), is a biopharmaceutical company utilizing its proprietary PTR™ drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of neurological disorders, Cingulate is identifying and evaluating additional therapeutic areas where PTR™ technology may be employed to develop future product candidates, including to treat anxiety disorders. Cingulate is headquartered in Kansas City. For more information visit Cingulate.com. Investor Contact: Thomas Dalton Vice President, Investor & Public Relations, Cingulate TDalton@cingulate.com 913-942-2301 Matt Kreps Darrow Associates Investor Relations 214-597-8200 mkreps@darrowir.com

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构